Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for CV Sciences (CVSI) over the last 10 years, with Q3 2025 value amounting to $1.5 million.

  • CV Sciences' Other Accumulated Expenses rose 66.98% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 66.98%. This contributed to the annual value of $1.4 million for FY2024, which is 588.62% down from last year.
  • Latest data reveals that CV Sciences reported Other Accumulated Expenses of $1.5 million as of Q3 2025, which was up 66.98% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, CV Sciences' Other Accumulated Expenses ranged from a high of $1.6 million in Q2 2025 and a low of $1.4 million during Q1 2024
  • In the last 4 years, CV Sciences' Other Accumulated Expenses had a median value of $1.5 million in 2025 and averaged $1.5 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 588.62% in 2024, then soared by 685.13% in 2025.
  • CV Sciences' Other Accumulated Expenses (Quarter) stood at $1.5 million in 2022, then decreased by 2.39% to $1.5 million in 2023, then decreased by 5.89% to $1.4 million in 2024, then increased by 5.62% to $1.5 million in 2025.
  • Its Other Accumulated Expenses stands at $1.5 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.5 million for Q1 2025.